Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 4
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07258225Phase 4Active Not Recruiting

Clinical Effectiveness of a Once-daily Regimen of Tigecycline Compared to the Standard Regimen

Role: lead

NCT05586646Not ApplicableUnknown

Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients

Role: lead

NCT04508946Phase 3Completed

Triple Therapy in Septic Shock Patients

Role: lead

All 3 trials loaded